The Delta variant: UK a test-case for re-opening and vaccine impact?

The Delta variant: UK a test-case for re-opening and vaccine impact?

In recent weeks, market sentiment has stuttered as investors evaluate the cases of the Delta variant of the Covid-19 virus. However, vaccines are proving to be highly effective against it. In countries with a high proportion of vaccinated adults, the number of infections resulting in severe cases (leading to hospitalisations and deaths) is now significantly lower than before vaccination programs had begun in earnest. Whilst this remains a challenging time for global health authorities and the human impact of the virus’ spread must not be overlooked, we believe that vaccine roll-outs could drive the market impact of the Delta variant’s spread, particularly when it comes to selecting across global equity regions.

We believe re-opening will continue in many developed countries - albeit with bumps along the way - supporting economic growth and increased consumer spending. This should be especially noticeable in countries that have had a quicker and more complete vaccine roll-out, such as the UK, where Fidelity Solutions & Multi Asset takes a positive view on the UK equities. At the same time, the team’s latest core views include a slightly more positive outlook for US equities, moving from neutral in previous months. Overall, the team takes a generally more favourable view on developed equity markets versus emerging markets and Asia Pacific ex Japan, where vaccine roll-outs are yet to gain as much traction, or are likely to have less impact due to already-contained pandemic situations.

Of course, the global vaccine roll-out is not the only dynamic shaping global markets, and we know that the summer months often bring a period of consolidation. This summer, we are moving from early- to mid-cycle, and are past ‘peak accommodation’ by central banks. As a result, the team has pared back some risk overall, remaining highly selective in our risk-on positioning, watching for better opportunities to add risk over the coming months.

UK data suggests vaccines help prevent instances of severe Covid-19, despite high infection rates

Source: Mathieu, E., Ritchie, H., Ortiz-Ospina, E. et al. A global database of COVID-19 vaccinations. Nat Hum Behav (2021), 22 July 2021.

This document is issued by FIL Responsible Entity (Australia) Limited ABN 33 148 059 009, AFSL No. 409340 (“Fidelity Australia”). Fidelity Australia is a member of the FIL Limited group of companies commonly known as Fidelity International.

This document is intended for use by advisers and wholesale investors. Retail investors should not rely on any information in this document without first seeking advice from their financial adviser. This document has been prepared without taking into account your objectives, financial situation or needs. You should consider these matters before acting on the information.  You should also consider the relevant Product Disclosure Statements (“PDS”) for any Fidelity Australia product mentioned in this document before making any decision about whether to acquire the product. The PDS can be obtained by contacting Fidelity Australia on 1800 119 270 or by downloading it from our website at This document may include general commentary on market activity, sector trends or other broad-based economic or political conditions that should not be taken as investment advice. Information stated herein about specific securities is subject to change. Any reference to specific securities should not be taken as a recommendation to buy, sell or hold these securities. While the information contained in this document has been prepared with reasonable care, no responsibility or liability is accepted for any errors or omissions or misstatements however caused. This document is intended as general information only. The document may not be reproduced or transmitted without prior written permission of Fidelity Australia. The issuer of Fidelity’s managed investment schemes is FIL Responsible Entity (Australia) Limited ABN 33 148 059 009. Reference to ($) are in Australian dollars unless stated otherwise.

© 2021 FIL Responsible Entity (Australia) Limited. Fidelity, Fidelity International and the Fidelity International logo and F symbol are trademarks of FIL Limited.

Share:
 
 

Want more insights like this?

Get our free, monthly e-newsletter bringing you valuable insights, opinion and education.

Subscribe